Human serum albumin-based nanoparticles alter raloxifene administration and improve bioavailability
Shu‐Jyuan Yang, Chih‐Hao Chang, Tai‐Horng Young, Chung‐Hao Wang, Tzu-Hao Tseng, Man‐Ling Wang
Abstract
results indicated that raloxifene molecules were well distributed in HSA-based nanoparticles as an amorphous state, and the resulting raloxifene formulation was stabile during long-term storage duration. The Ral/HSA/PSS NPs were both biocompatible and hemocompatible with a decreased cytotoxicity of high-dose raloxifene. Moreover, the intravenous administration of the prepared Ral/HSA/PSS NPs to rats improved raloxifene bioavailability and improved its half-life in plasma. These raloxifene-loaded nanoparticles may be a potential nanomedicine candidate for treating postmenopausal osteoporosis with lower raloxifene dosages.
Topics & Concepts
RaloxifeneBioavailabilityPharmacologySelective estrogen receptor modulatorOsteoporosisHuman serum albuminMedicineEstrogenChemistryEndocrinologyInternal medicineEstrogen receptorBiochemistryBreast cancerCancerEstrogen and related hormone effectsBone health and osteoporosis researchVitamin D Research Studies